论文部分内容阅读
目的探讨瑞舒伐他汀治疗急性冠脉综合征(ACS)的临床疗效及其对患者血清超敏C反应蛋白(hs-CRP)的影响。方法选取芜湖市第一人民医院2014年10月—2016年3月收治的ACS患者86例,采用随机数字表法将患者分为对照组和观察组,各43例。对照组患者给予常规基础治疗,观察组在对照组基础上给予瑞舒伐他汀治疗,两组患者均持续治疗1个月。比较两组患者治疗前后血脂指标[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)及低密度脂蛋白胆固醇(LDL-C)]及治疗前、治疗后2周、治疗后4周血清hs-CRP水平。结果治疗前,两组患者TC、TG、LDL-C及HDL-C比较,差异无统计学意义(P>0.05);治疗后,观察组患者TC、TG、LDL-C低于对照组,HDL-C高于对照组(P<0.05)。治疗前,两组患者血清hs-CRP水平比较,差异无统计学意义(P>0.05);治疗后2、4周,观察组患者血清hs-CRP水平低于对照组(P<0.05)。结论瑞舒伐他汀治疗ACS临床疗效确切,可有效改善血脂指标,降低血清hs-CRP水平。
Objective To investigate the clinical efficacy of rosuvastatin in the treatment of acute coronary syndrome (ACS) and its effect on serum hs-CRP in patients. Methods Eighty-six ACS patients were selected from the First People’s Hospital of Wuhu City from October 2014 to March 2016. The patients were divided into control group and observation group with 43 cases in each group by random number table. Patients in the control group were given routine basic treatment. The observation group was treated with rosuvastatin on the basis of the control group, and both groups were treated for one month. The levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) before and after treatment were compared between the two groups before and after treatment 2 weeks, 4 weeks after treatment serum hs-CRP levels. Results Before treatment, TC, TG, LDL-C and HDL-C in the two groups had no significant difference (P> 0.05). After treatment, TC, TG and LDL-C in the observation group were lower than those in the control group -C higher than the control group (P <0.05). Before treatment, serum hs-CRP levels in the two groups were not significantly different (P> 0.05). After 2 and 4 weeks of treatment, serum hs-CRP level in the observation group was lower than that in the control group (P <0.05). Conclusion Rosuvastatin treatment of ACS clinical curative effect, can effectively improve blood lipid indicators, reduce serum hs-CRP levels.